Abstract
Premenstrual syndrome (PMS) was first mentioned in a paper by Dr. Robert Frank in 1931, and further described and defined in the British Medical Journal in 1953 (1). PMS is a common condition characterized by physical and behavioral symptoms that occur during the luteal phase of the menstrual cycle. The luteal phase is defined as the time in the menstrual cycle that occurs between ovulation and menstruation. Symptoms include abdominal bloating, headaches, breast tenderness and fatigue, which do not significantly impair the day-to-day activities of the woman’s lifestyle. These symptoms have been reported to affect as many as 75% of women of reproductive age.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dalton K, Greene R. The premenstrual syndrome. Brit Med J 1953;1:1007.
Adapted from Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. Washington DC: American Psychiatric; 1994.
Wittchen H, Becker E, Lieb R, Krause P. Prevalence, incidence, and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32(1):119–132.
Steiner M, Born L. Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 2000;15:S5–S17.
Girdler S, Straneva P, Light KC, Pedersen CA, Morrow AL. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 2001;49(9):788–797.
Haslbreich U, Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndromes. Int J Psychiatry Med 1993;23(1):1–27.
Endicott, J. Differential diagnosis and comorbidity. In: Premenstrual Dysphorias: Myths and Realities (Gold J, Severino S, eds.). American Psychiatric, Washington DC, 1994; pp. 3–17.
American College of Obstetricians and Gynecologists. Premenstrual syndrome: clinical management guidelines for obstetrician-gynecologists. ACOG Practice Bulletin 2000; 15:1–9.
Wyatt K, Dimmock P, Jones PW, Shaughn O’Brien PM. Efficacy of vitamin B6 in the treatment of the premenstrual syndrome: systematic review. BMJ 1999;318:1375–1381.
Hardy M. Herbs of special interest to women. J Am Pharm Assoc 2000;40:234–242.
Lam R, Carter D, Misri S, Kuan AJ, Yatham LN, Zis AP A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res 1999;86:185–192.
Cohen L, Soares C, Yonkers KA, Bellew KM, Bridges IM, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo controlled trial. Psychosomatic Med 2004;66:707–713.
Cohen L. Sertraline for premenstrual dysphoric disorder. JAMA 1998;279:357–358.
Veeninga AT, Westenberg HG, Weusten JT. Fluvoxamine in the treatment of menstrually related mood disorders. Psychopharmacol 1990;102:414–416.
Pearlstein T, Joliat M, Brown EB, Miner CM. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment. Am J Obstet Gynecol 2003:188:887–895.
Lin J, Thompson D. Treating premenstrual dysphoric disorder using serotonin agents. J Womens Health Gen Based Med 2001; 10:745–750.
Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, doubleblind, placebo-controlled clinical trial. Clin Ther 2002;24:417–433.
Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria. Acta Psychiatr Scand 1992;85:39–47.
Cohen LS, Soares CN, Lyster A, Cassano P, Brandes M, Leblanc GA. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharm 2004;24(5):540–543.
Halbreich U, Petty F, Yonkers K, Kramer GL, Rush AJ, Bibi KW. Low plasma gammaaminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry 1996;153:718–720.
Evans S, Haney M, Levin FR, Foltin RW, Fischman MW. Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam. Neuropsychopharmacology 1998; 19:499–516.
Leather A, Studd J, Watson NR, Holland EF. The treatment of severe premenstrual syndrome with goserelin with and without add-back estrogen therapy. Gynecol Endocrinol 1999; 13:48–55.
Freeman E, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gen Based Med 2001;10:561–569.
Hahn P, Van Vugt D, Reid R. A randomized, placebo-controlled, crossover trail of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995;20:193–209.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Cohen, H.B. (2008). Premenstrual Syndrome and Premenstrual Dysphoric Disorder. In: Clouse, A.L., Sherif, K. (eds) Women’s Health in Clinical Practice. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-469-8_2
Download citation
DOI: https://doi.org/10.1007/978-1-59745-469-8_2
Publisher Name: Humana Press
Print ISBN: 978-1-58829-631-3
Online ISBN: 978-1-59745-469-8
eBook Packages: MedicineMedicine (R0)